Cognition Therapeutics announces availability of CEO shareholder letter

Reuters04-01

Cognition <a href="https://laohu8.com/S/LENZ">Therapeutics</a> announces availability of CEO shareholder letter

Cognition Therapeutics announced availability of CEO Lisa Ricciardi shareholder letter at .
Letter outlined plan to advance zervimesine (CT1812) into late-stage development for dementia with Lewy bodies psychosis, with FDA Division of Psychiatry meeting expected in Q2 2026.
Ricciardi highlighted Phase 2 SHIMMER data in mild-to-moderate DLB, citing strongest signals in Neuropsychiatric Inventory measures of behavior and psychosis.
Update flagged Phase 2 START trial in mild cognitive impairment or early Alzheimer’s disease, with readout expected in 2H 2027.
Letter said START is fully funded by NIH grant, covering about USD 80 million in costs through study completion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. published the original content used to generate this news brief on March 31, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624530008?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 04:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624530008","market":"fut","top_or_hot":-1,"title":"Cognition Therapeutics announces availability of CEO shareholder letter","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cognition <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> announces availability of CEO shareholder letter\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Cognition Therapeutics announced availability of CEO Lisa Ricciardi shareholder letter at .\n        </li>\n<li>\n          Letter outlined plan to advance zervimesine (CT1812) into late-stage development for dementia with Lewy bodies psychosis, with FDA Division of Psychiatry meeting expected in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026.\n        </li>\n<li>\n          Ricciardi highlighted Phase 2 SHIMMER data in mild-to-moderate DLB, citing strongest signals in Neuropsychiatric Inventory measures of behavior and psychosis.\n        </li>\n<li>\n          Update flagged Phase 2 START trial in mild cognitive impairment or early Alzheimer’s disease, with readout expected in 2H 2027.\n        </li>\n<li>\n          Letter said START is fully funded by NIH grant, covering about USD 80 million in costs through study completion.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. published the original content used to generate this news brief on March 31, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cognition Therapeutics announces availability of CEO shareholder letter</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCognition Therapeutics announces availability of CEO shareholder letter\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-04-01 04:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cognition <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> announces availability of CEO shareholder letter\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Cognition Therapeutics announced availability of CEO Lisa Ricciardi shareholder letter at .\n        </li>\n<li>\n          Letter outlined plan to advance zervimesine (CT1812) into late-stage development for dementia with Lewy bodies psychosis, with FDA Division of Psychiatry meeting expected in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026.\n        </li>\n<li>\n          Ricciardi highlighted Phase 2 SHIMMER data in mild-to-moderate DLB, citing strongest signals in Neuropsychiatric Inventory measures of behavior and psychosis.\n        </li>\n<li>\n          Update flagged Phase 2 START trial in mild cognitive impairment or early Alzheimer’s disease, with readout expected in 2H 2027.\n        </li>\n<li>\n          Letter said START is fully funded by NIH grant, covering about USD 80 million in costs through study completion.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. published the original content used to generate this news brief on March 31, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CGTX","symbol_name":"Cognition Therapeutics, Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLbhM7WM:1","article_id":"2624530008","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624530008","pubTimestamp":1774989684,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cognition Therapeutics announced availability of CEO Lisa Ricciardi shareholder letter at .Letter outlined plan to advance zervimesine  into late-stage development for dementia with Lewy bodies psychosis, with FDA Division of Psychiatry meeting expected in Q2 2026.Ricciardi highlighted Phase 2 SHIMMER data in mild-to-moderate DLB, citing strongest signals in Neuropsychiatric Inventory measures of behavior and psychosis.Update flagged Phase 2 START trial in mild cognitive impairment or early Alzheimer’s disease, with readout expected in 2H 2027.Letter said START is fully funded by NIH grant, covering about USD 80 million in costs through study completion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. publish","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CGTX":"Cognition Therapeutics, Inc","BK4007":"制药"},"translate_title":"Cognition Therapeutics宣布发布首席执行官股东信","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CGTX":0.9},"content_text":"Cognition Therapeutics announces availability of CEO shareholder letter\n    \n\n\n          Cognition Therapeutics announced availability of CEO Lisa Ricciardi shareholder letter at .\n        \n\n          Letter outlined plan to advance zervimesine (CT1812) into late-stage development for dementia with Lewy bodies psychosis, with FDA Division of Psychiatry meeting expected in Q2 2026.\n        \n\n          Ricciardi highlighted Phase 2 SHIMMER data in mild-to-moderate DLB, citing strongest signals in Neuropsychiatric Inventory measures of behavior and psychosis.\n        \n\n          Update flagged Phase 2 START trial in mild cognitive impairment or early Alzheimer’s disease, with readout expected in 2H 2027.\n        \n\n          Letter said START is fully funded by NIH grant, covering about USD 80 million in costs through study completion.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. published the original content used to generate this news brief on March 31, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624530008","isCrawlerRequest":true}